The purpose of this study is to investigate repeated doses of Lu AF28996 in healthy participants and co-administered with two other compounds, and in a separate cohort following co-administration with antibiotics, to see how well the doses are tolerated and what the body does to the drug after administering it.
The study has 2 parts: Part A and Part B. Part A will consist of 2 cohorts (Cohorts A1 to A2), with 8 participants per cohort and will receive single doses of Lu AF28996 alone and in combination with enzyme inhibitors. Part B will consist of one cohort (Cohort B1), with 8 participants who will all receive single doses of Lu AF28996 alone and in combination with amoxicillin/clavulanic acid.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Covance Dallas CRU
Dallas, Texas, United States
Maximum Observed Concentration (Cmax) of Lu AF28996
Time frame: Predose to Day 13
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Lu AF28996
Time frame: Predose to Day 13
Nominal Time Corresponding to the Occurrence of Cmax
Time frame: Predose to Day 13
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tablet